Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Alkermes presents phase II data on ALKS-33 in alcohol dependence

Dec. 10, 2010

CBLB-502 receives FDA orphan drug status for prevention of death following irradiation

Dec. 1, 2010

Enrollment completed in Nabi Biopharma' second phase III NicVAX trial

Nov. 10, 2010

Nicotine vaccine NIC-002 enters phase II study

Nov. 8, 2010

AEOL-10150 promotes survival in nonhuman primates exposed to radiation

Nov. 5, 2010

Soligenix presents preliminary phase Ib safety data on RiVax

Nov. 4, 2010

Alkermes' combination therapy for cocaine addiction to advance to phase II

Oct. 26, 2010

Omeros receives additional grant from NIDA for addiction program

Oct. 18, 2010

FDA approves Vivitrol for prevention of relapse to opioid dependence

Oct. 13, 2010

Embera NeuroTherapeutics obtains NIDA grant for EMB-001 development

Oct. 5, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...